Phase I Study of Oxaliplatin in Combination With Capecitabine and Radiotherapy as Postoperative Treatment for Stage II and III Rectal Cancer

OXA combined with a fixed dose of capecitabine at 625 mg/m2 twice daily by mouth plus radiotherapy in the adjuvant setting was tolerable and clinically feasible. The maximal tolerated dose of OXA in this setting was 80 mg/m2, comparable to the maximal tolerated dose of OXA in the neoadjuvant setting.